🔍 New Publication Alert! Understanding the Real Prevalence of Interstitial Lung Disease in Rheumatoid Arthritis Patients In the realm of rare diseases, accurately estimating prevalence is a significant challenge. Literature suggests a wide prevalence range for interstitial lung disease associated with Rheumatoid Arthritis (RA) - from 1% to 60%. This vast variability poses real-world difficulties in diagnosis, treatment planning, and resource allocation, impacting patient care and research focus. 📊 Our recent study, published in RMD Open, leverages machine learning and big data to shed light on this issue. By analyzing a cohort of 14,000 RA patients, we've derived reliable real-world data, estimating that this condition affects 1 in every 20 patients. This finding narrows the prevalence gap and provides a clearer target for healthcare providers and researchers. This work was made possible through collaboration with esteemed institutions and colleagues, including various Spanish hospitals, the innovative team at SAVANA Med, and the support of Bristol Myers Squibb (BMS) and Sandra Orta. I extend my heartfelt gratitude to @Jose Andres Roman Ivorra, Ignacio H. Medrano and Diego Benavent Nuñez for their significant contributions and unwavering commitment to this project. 📝 Our findings underscore the power of technology in transforming medical research and patient care. Dive into our publication to explore how big data and machine learning are unveiling the real face of rare disease prevalence: https://lnkd.in/dZ-Gdd8n #RheumatoidArthritis #InterstitialLungDisease #MachineLearning #BigData #MedicalResearch #BMSiberia #HealthcareInnovation #SAVANAMed
Raul A. Castellanos Moreira MD/ Rheumatologist/ PhD’s Post
More Relevant Posts
-
We are happy to share the latest publication from Ariel Precision Medicine following our mission to advance a deeper understanding of the impact of Recurrent Acute and Chronic Pancreatitis. https://lnkd.in/gQk4mBSw Traditional research studies have considered hospital admissions as the gold standard for measuring the attack rate and thus healthcare burden for Recurrent Acute and Chronic Pancreatitis. In hopes of better estimating the burden of disease, we reached out to patients to fill out a brief questionnaire focused on pancreatic events that are managed "outside" of a hospital or ER setting. We discovered that patients suffer through multiple events per year that are managed outside of the hospital setting, highlighting that true event rate may be significantly underrepresented in the literature. Gaining a better understanding of the impact of pancreatic disease and event rate is foundational to developing targeted therapeutics and more effective treatments aimed at improving patient lives and health outcomes. Congratulations to Phil Greer, Jessica Gibson, Tory Moore, CFA and David C Whitcomb MD PhD #healthoutcomes #precisionmedicine #datascience #pancreatitis
To view or add a comment, sign in
-
-
🎉 Exciting progress in the understanding of autoimmune diseases and their prevalence in women has recently been made by a team of researchers at Stanford University 🎉 4 out of 5 autoimmune patient are women, and a group of scientists may have found out why. The mysteries behind why women are at a higher risk for conditions like multiple sclerosis, lupus, and rheumatoid arthritis have long puzzled the medical field, but this new study sheds light on a potential explanation. It seems that the female body's management of its extra X chromosome may play a role in making women more susceptible to these autoimmune disorders, which involve the immune system attacking its own cells and tissues. This groundbreaking research, though in its early stages with experiments conducted on mice, could pave the way for new treatments and diagnostic methods for these chronic conditions. At Viuhealth, we are dedicated to helping healthcare providers better manage patients with autoimmune conditions like multiple sclerosis, lupus, rheumatoid arthritis, and more. Our platform uses advanced technology and data analytics to streamline patient care, improve treatment outcomes, and enhance the overall patient experience. By staying on top of the latest research and breakthroughs in autoimmune disease management, we are able to provide healthcare providers with the tools and resources they need to deliver personalized and effective care to their patients. The findings from the Stanford University study are just one example of how ongoing research can lead to innovative solutions that benefit both healthcare professionals and the individuals they treat. Check out the full article here: https://lnkd.in/esEMrqER #autoimmunedisease #autoimmune #healthcare #innovation
To view or add a comment, sign in
-
-
Important focus on understanding the pathophysiology of Lean MASLD
“While lean NAFLD (MASLD) may be less common than its obese counterpart, it is a significant health issue that requires further research and understanding. The use of advanced technologies like machine learning and deep learning can potentially enhance our understanding and treatment of this complex disease.” “As we learn more about lean NAFLD, it’s essential for healthcare providers and patients alike to be aware of its risks and management strategies to improve health outcomes for those affected.” This “study, which used computed tomography (CT) imaging to identify patients with hepatic steatosis, found that 24.0% of the patients in the cohort had hepatic steatosis, and 13.0% of these were lean. This underscores the fact that NAFLD is not exclusive to obese or overweight populations, and lean individuals can also develop the disease.”
To view or add a comment, sign in
-
Gestational Trophoblastic Disease Global Market Report 2024 . The gestational trophoblastic disease market size has grown strongly in recent years. It will grow from $1.96 billion in 2023 to $2.06 billion in 2024 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to public health initiatives, improved understanding of disease pathology, medical research and clinical trials, development of targeted therapies, shift in treatment protocols. . The gestational trophoblastic disease market size is expected to see steady growth in the next few years. It will grow to $2.49 billion in 2028 at a compound annual growth rate (CAGR) of 4.8%. Read More @ https://lnkd.in/gHUw32Hb . #marketresearch #marketintelligence #marketreport #industryanalysis #TheBusinessResearchCompany #TBRC #GlobalMarketModel
To view or add a comment, sign in
-
-
The global burden of chronic diseases is staggering, with #noncommunicable diseases (NCDs) responsible for 74% of global deaths annually. As we face this health crisis, diagnostic imaging emerges as a critical tool in managing these conditions. Key facts: • NCDs cause 41 million deaths yearly (WHO, 2023) • Cardiovascular diseases lead with 17.9 million deaths • Cancer follows at 9.3 million deaths The role of imaging in chronic disease management is invaluable: • Cardiovascular care: Echocardiography, CT angiography, MRI • Oncology: PET scans, MRI, CT for tumor detection and staging • Neurology: MRI and CT for diagnosing conditions like stroke and Alzheimer's As chronic diseases rise, so does the demand for advanced imaging. The Global Diagnostic Imaging Services Market reflects this trend: • 2023 valuation: USD 580.71 Billion • 2029 projected value: USD 812.20 Billion • Expected CAGR: 5.95% 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐑𝐞𝐩𝐨𝐫𝐭 - https://lnkd.in/gpYDdUPP Siemens Healthineers AG, GE HealthCare Technologies Inc., Koninklijke Philips N.V., FUJIFILM Holdings Corporation, Canon EMEA Inc., Hitachi, Ltd., Carestream Health, Inc., Hologic, Inc., AGFA HealthCare N.V., Samsung Medison Co., Ltd. #HealthcareInnovation #DiagnosticImaging #ChronicDiseaseManagement
To view or add a comment, sign in
-
-
Despite facing challenges in 2022, the clinical trials landscape highlighted oncology as the leading therapeutic area, with infectious diseases also showing significant activity. These areas underscore the healthcare industry's commitment to addressing both enduring and emerging health challenges. With a detailed analysis of trials across various therapeutic areas, the landscape reflects a focused drive towards critical healthcare advancements. Uncover more insights into therapeutic area trends in Citeline's latest industry report: https://lnkd.in/gGzP7yTK #ClinicalTrials #OncologyResearch #InfectiousDiseases #HealthcareInnovation
To view or add a comment, sign in
-
-
This morning at the Alzheimer's Association® International Conference (AAIC) 2024 in Philadelphia, we presented data from a recent study that further demonstrates the high accuracy of our blood tests incorporating the ALZpath Inc. proprietary pTau217 antibody for Alzheimer’s disease diagnosis. Our latest study, involving over 50,000 samples from 40 cohort studies, highlights the precision of the pTau217 antibody in determining amyloid burden across all stages of Alzheimer’s disease progression. This supports early detection, treatment, and tracking. "The need for accurate and convenient testing methods, such as blood tests, has never been more evident," says Chad Holland, CEO of ALZpath. Our pTau217 antibody is a game-changer, offering a less invasive and more accessible alternative to traditional diagnostic methods. Read the full press release here: https://lnkd.in/gFjhVS3C To learn more about ALZpath and our innovative solutions, visit https://alzpath.bio/ and follow us here on LinkedIn for the latest updates. #Alzheimers #AlzheimersResearch #AAIC2024 #HealthcareInnovation #BloodTests #EarlyDetection #pTau217
To view or add a comment, sign in
-
-
🧠 “Alzheimer’s Disease is a major healthcare issue in rural and regional populations and ageing is the biggest contributing factor.” Can the use of Medical Resonance Imaging (MRI) be used as a tool for the early detection of Alzheimer’s Disease? It's a question Charles Sturt University's Dr Xiaoming Zheng hopes to answer with new research he is leading in Wagga Wagga. Dr Zheng and his team are investigating how MRI scans can be used to spot Alzheimer’s before it progresses, potentially revolutionising how we detect and treat this challenging disease. 🧠 “Earlier detection is critical but there is no effective tool for the screening of the disease and often patients have already developed into an advanced stage of the disease when clinical symptoms appear. “Evidence suggests that Alzheimer’s Disease drugs focused on reducing or removing amyloid deposit or hyperphosphorylated tau (current methods of treatment) are not effective, so we need to find a different strategy in drug development to be able to effectively treat this disease.” ➡️ It is hoped this new research will lead to earlier detection, more effective and targeted therapies and new directions for Alzheimer’s medication. #CharlesSturtResearch #RuralHealthCare TEQSA PRV12018 (Australian University) CRICOS 000005F
To view or add a comment, sign in
-
A 2021 study reveals that early involvement of dietitians may slow or stabilize weight loss in the care of epigastric cancer patients. Three key take-aways for practicing oncologists are: (1) clarify the difference between weight loss and cachexia, (2) identify precachexia and (3) refer early to dietitians. Agilix Health addresses the issue of precachexia and cachexia amongst cancer patients by offering tech-enabled, reimbursable nutrition services that combine remote patient monitoring with virtual support from specialized Registered Dietitians. #cachexia #nutritionservices #remotepatientmonitoring #AgilixHealth
To view or add a comment, sign in
-